Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $300.8 million.

  • Iovance Biotherapeutics' Cash & Current Investments rose 8322.76% to $300.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.8 million, marking a year-over-year increase of 8322.76%. This contributed to the annual value of $323.8 million for FY2024, which is 1569.1% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Cash & Current Investments stood at $300.8 million for Q3 2025, which was up 8322.76% from $301.2 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cash & Current Investments registered a high of $626.3 million during Q1 2023, and its lowest value of $164.2 million during Q3 2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $301.2 million (2025), whereas its average is $323.0 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Cash & Current Investments plummeted by 5457.2% in 2024 and then soared by 8322.76% in 2025.
  • Iovance Biotherapeutics' Cash & Current Investments (Quarter) stood at $279.9 million in 2023, then rose by 15.69% to $323.8 million in 2024, then dropped by 7.09% to $300.8 million in 2025.
  • Its Cash & Current Investments was $300.8 million in Q3 2025, compared to $301.2 million in Q2 2025 and $359.7 million in Q1 2025.